Welcome to our dedicated page for IRIDEX SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRIDEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRIDEX's regulatory disclosures and financial reporting.
Novel Inspiration International Co., Ltd. and Shih‑Yao David Lin report beneficial ownership of 5,351,483 IRIDEX Corporation shares, or 24.1% of the common stock. Their position comes from 600,000 shares of Series B Preferred Stock purchased at $10.00 per share and a $4,000,000 convertible promissory note, both convertible into a total of 5,000,000 common shares, plus 351,483 common shares issued as interest on the note. The note carries 12% annual interest, payable quarterly in common stock based on a formula tied to market price and a minimum price of $0.21 per share.
Novel Inspiration and Mr. Lin describe the investment as for investment purposes but indicate plans to engage with IRIDEX’s board and management on strategy, capital structure, and potential transactions, including possible mergers, acquisitions, or a going‑private deal. An Investor Rights Agreement gives Novel Inspiration registration rights, the ability—subject to ownership thresholds—to appoint up to two directors, and approval rights over certain corporate actions, increasing their potential influence over the company’s governance and strategic direction.
IRIDEX Corporation director reports open-market stock purchase
A director of IRIDEX Corporation reported buying 2,000 shares of common stock on 12/16/2025 at a price of $1.0099 per share. After this transaction, the director beneficially owns 251,550 shares directly and 69,300 shares indirectly through a spouse. An additional 81,150 shares are held indirectly through the William M. Moore Trust and the Patricia A. Moore Trust, which hold the shares as tenants in common under trust agreements dated August 16, 2016 and August 17, 2016, respectively.
IRIDEX director William M. Moore reported buying 20,000 shares of IRIDEX common stock on 12/15/2025, shown as a purchase transaction.
The shares were acquired in multiple trades at weighted average prices between $0.98 and $0.9885 per share. Following this transaction, Moore directly owned 249,550 IRIDEX shares, with an additional 69,300 shares held indirectly by his spouse and 81,150 shares held indirectly through the William M. Moore Trust and the Patricia A. Moore Trust as tenants in common.
Iridex Corp director reported buying additional company common stock in December 2025. On December 11, 2025, the director purchased 9,080 shares at a weighted average price between $0.9508 and $0.97. On December 12, 2025, the director purchased a further 20,920 shares at a weighted average price between $0.9205 and $0.97, bringing direct beneficial ownership to 280,674 shares of Iridex common stock.
The report also discloses indirect holdings of 69,300 shares held by the director’s spouse and 30,026 shares held through the William M. Moore Trust and the Patricia A. Moore Trust as tenants in common.
IRIDEX Corp's chief financial officer, Romeo R. Dizon, reported acquiring 2,365 shares of common stock on 12/12/2025 at $0.9709 per share. Following this purchase, his direct ownership increased to 92,685 IRIDEX common shares, as disclosed in the Form 4 insider transaction report.
IRIDEX Corporation filed a current report to highlight its participation in the Sidoti Year-End Virtual Investor Conference on December 11, 2025. A live webcast of the presentation is scheduled to begin at 10:45 a.m. Eastern Time and will be available, along with an archived version, in the investors section of the company’s website at www.IRIDEX.com.
The company is also making available a set of presentation materials as Exhibit 99.1. These materials are being furnished, not filed, under Regulation FD, meaning they are shared for information purposes and are not treated as part of the company’s formal financial reporting under Section 18 of the Exchange Act.
IRIDEX CORP reported that its Chief Financial Officer, Romeo R. Dizon, bought additional company stock. On 11/20/2025, he acquired 5,760 shares of common stock in an open market purchase at a price of $0.96 per share. After this transaction, he beneficially owned 88,736 shares of IRIDEX common stock directly.
IRIDEX Corporation (IRIX) reported an insider share purchase by its Chief Financial Officer, Romeo R. Dizon. On 11/19/2025, the CFO bought 1,000 shares of common stock at $0.96 per share in an open-market purchase, bringing his directly owned holdings to 82,976 shares. This activity was reported on a Form 4 filed for a single reporting person.
IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On 11/18/2025, he bought 2,133 shares of IRIDEX common stock at a price of $0.94 per share, as shown in Table I of the filing. After this transaction, he beneficially owned 81,976 shares of IRIDEX common stock in direct ownership. This report was filed as a Form 4 by a single reporting person, indicating a change in his personal holdings of IRIDEX equity.
IRIDEX Corporation (IRIX) director share purchases disclosed. A company director reported open-market purchases of common stock in two transactions. On 11/14/2025, the director bought 28,157 shares at a weighted average price of $0.9676 per share, in multiple trades between $0.9367 and $0.98. On 11/17/2025, the director bought 21,843 shares at a weighted average price of $0.9654 per share, in multiple trades between $0.95 and $0.98.
After these transactions, the director beneficially owns 250,674 shares directly. In addition, 69,300 shares are held indirectly by the director’s spouse, and 30,026 shares are held indirectly through trusts identified in the footnotes. The filing notes that detailed trade‑by‑trade pricing information is available upon request.